IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the World Intellectual Property Organization, WIPO, has published a new patent application concerning drug candidate mesdopetam (IRL790). This composition of matter patent may extend the market exclusivity of mesdopetam by up to eight years compared with the current patent protection. WIPO also published an International Search Report (ISR) and a patentability statement, Written Opinion (WO), in conjunction with the publication of IRLAB’s patent application. Mesdopetam is currently being evaluated in a clinical Phase IIb/III study for the